Three months after getting the coveted Good Manufacturing Practices (GMP) approval from the United Nations International Children's Emergency Fund (UNICEF), Panchkula-based pharmaceutical company Venus Remedies has been awarded a tender by UNICEF for supplying ceftriaxone (1gm), a beta-lactam antibiotic, in dry powder form.

Ceftriaxone dry powder is an important drug in Venus Remedies’ extensive antibiotic portfolio. Moreover, ceftriaxone is an important antibiotic globally due to its broad-spectrum activity and effectiveness in treating a variety of serious bacterial infections.

The global ceftriaxone market was valued at $1.7 billion in 2021 and is expected to grow at a CAGR of 2.9% from 2022 to 2031 to reach over $2.2 billion by the end of 2031.

In another development crucial to improving healthcare outcomes in Latin America, Venus Remedies has been awarded an oncology tender by the WHO-backed Pan American Health Organisation (PAHO), the world's oldest international public health agency.

The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs like bleomycin, carboplatin, cisplatin, cytarabine, doxorubicin, irinotecan, methotrexate and vincristine.